<DOC>
	<DOC>NCT01613027</DOC>
	<brief_summary>This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate response to one or more tumour necrosis factor inhibitor (anti-TNF) therapies.</brief_summary>
	<brief_title>An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age &gt;18 years with rheumatoid arthritis (RA) Seropositive participants with RA (positive for rheumatoid factor (RF) and/or antiCitrullinated Cyclic Peptide [CCP]) Active disease despite receiving one or more TNF inhibitors Absence of serious or active infection Participants with serious history of heart failure (class New York Heart Association [NYHA] IV) or severe uncontrolled heart disease Participants pregnant or lactating Prior treatment with MabtheraÂ® Participants receiving any other investigational product in the context of other clinical study Participants with known hypersensitivity to rituximab or to any of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>